July 2026 Research Update

Across this group of papers, the main pattern was that diagnosing and monitoring Langerhans cell histiocytosis (LCH) often required combining body imaging with tissue testing, especially when LCH appeared in uncommon sites or looked more extensive on scans than it proved to be on pathology. A small comparative imaging study suggested some situations where one whole-body scan type may show more detail, while also showing limits for lung assessment. Separate early-stage research and a small case series explored blood-based tests that might help identify pituitary hormone-related problems, but these approaches need more validation. [1] [2] [3] [4] [5] [6] [7]

In a prospective single-center study of 15 people with systemic histiocytosis (including LCH), whole-body PET/MRI and PET/CT were mostly in agreement (14 of 15 patients). PET/MRI found additional lesions or clarified lesions in 5 of 15 patients, including a brainstem lesion seen only on PET/MRI that led clinicians to re-evaluate the treatment plan, while PET/CT performed better for evaluating lung lesions. [1]

Several case reports illustrated that imaging alone may not fully settle the diagnosis, and that tissue sampling with immune-marker staining can be central when the presentation is unusual. One 20-year-old woman with aggressive, multifocal bone disease needed three biopsies before LCH was confirmed with CD1a, S100, and Langerin positivity, showing how diagnosis can be delayed when early samples are not definitive. [5]

Other case reports highlighted organ sites where LCH can mimic other conditions and create uncertainty on imaging. In one 33-year-old woman with an anterior mediastinal mass, PET-CT suggested possible invasion, but surgery showed a well-encapsulated lesion and pathology found thymic hyperplasia with only a 3 mm LCH focus, suggesting imaging may overestimate extent in this setting. [4]

Uncommon gland involvement also came up as a diagnostic challenge. A 42-year-old woman with thyroid, salivary gland, and lung involvement underwent thyroid removal to clarify the diagnosis, and immune-marker testing (including CD1a and langerin positivity) confirmed LCH; a separate report described an adult with a painless parotid mass ultimately diagnosed as multisystem LCH and emphasized the need for a comprehensive diagnostic approach when rare sites are involved. [6] [7]

Two studies focused on tests that could support recognition of pituitary-related problems or earlier detection, but both were exploratory. A three-patient case series (including one person with LCH) used a blood test called copeptin to help identify arginine vasopressin deficiency, a cause of diabetes insipidus symptoms, and the authors proposed using it earlier in workups for systemic histiocytosis. [2]

In a pediatric study using blood metabolite profiling (56 children with LCH and 27 healthy controls), certain metabolite patterns differed between groups, with some signals linked to posterior pituitary involvement; a subset was also checked in spinal fluid in a small number of children. The study also explored cell pathway signals related to ferroptosis in immune cells, but the authors noted the need for larger, external validation before these markers could be considered reliable for diagnosis or monitoring. [3]

For patients and caregivers, these papers mainly reinforce why LCH care teams often use more than one kind of test over time: imaging to look for where disease is active across the body, and pathology (biopsy plus immune-marker staining) to confirm what the disease is, especially in uncommon locations like the mediastinum, thyroid, or salivary glands. The imaging comparison study suggests PET/MRI may add detail in some complex situations but may not replace PET/CT for lung assessment, while blood-based tests (copeptin and metabolite patterns) are still early-stage tools that may be relevant to pituitary-related complications but are not yet established for routine use based on the limited evidence here.

Across these reports, treatments being used for Langerhans cell histiocytosis (LCH) varied widely based on where the disease was and whether it had come back. Chemotherapy remained a common backbone, with some centers also using longer maintenance treatment, and some cases using local treatments such as steroid injections or radiotherapy when disease was limited to a specific area. Use of targeted drugs that block the MAPK pathway was frequently reported by clinicians for relapsed or treatment-resistant pediatric LCH, but this evidence here is based on a survey rather than patient outcome data. [8] [9] [10] [11] [12] [13]

In a small single-institution retrospective cohort of 15 people with single-system, single-site LCH needing systemic therapy, an induction chemotherapy approach based on cytarabine followed by a year of oral maintenance was linked with good or partial responses after induction and good responses after maintenance. With a median 5.6 years of follow-up, all patients were alive without relapse or central nervous system complications, and toxicity was limited mainly to temporary liver enzyme increases during maintenance. [8]

For children with relapsed LCH in a small North India series (7 patients), several salvage approaches were used, including cladribine-based chemotherapy, lenalidomide with dexamethasone, and surgery, with all children reported in complete remission at last follow-up. Intensive salvage episodes were often complicated by fever with low blood counts, while lenalidomide with dexamethasone was described as feasible as an outpatient option without significant toxicity in this report. Long-term health issues were still seen in some children, including persistent diabetes insipidus and hearing loss. [9]

Two case reports highlighted treatment choices for unusual or difficult-to-manage locations. In an adult with multisystem LCH affecting the hypothalamic-pituitary area and causing multiple hormone problems and central diabetes insipidus, initial chemotherapy led to only a small decrease in tumor size, and radiotherapy to the remaining hypothalamic lesion led to partial remission on scans. In an elderly woman with LCH limited to the colon and anal region, six cycles of cladribine led to complete symptom and endoscopic remission with tolerable side effects. [12] [13]

Local therapy was also described in a single patient with a skull lesion: combined injections of the steroid triamcinolone into and around the lesion were followed by rapid shrinkage over days and improved appearance on MRI. Because this is one patient, it cannot show how often this works or who is most likely to benefit. [10]

A clinician survey (106 pediatric attending physicians from 26 countries) described how targeted MAPK inhibitors are already being used in real-world pediatric LCH care, usually outside clinical trials and mainly for recurrent or hard-to-treat disease. Many clinicians supported running prospective trials that test MAPK inhibitors alone or combined with chemotherapy, including in higher-risk multisystem disease, but the survey did not provide patient outcome or side effect rates. [11]

For patients and caregivers, these papers show that LCH treatment in practice can include chemotherapy (sometimes followed by maintenance treatment), different salvage options if LCH returns, and sometimes localized treatments like radiotherapy or steroid injections when disease is confined to one area. Targeted MAPK-pathway drugs are being used by many pediatric specialists for relapsed or resistant LCH, but in this set of papers the strongest details on results come from small single-center studies and individual case reports, so it remains uncertain how well each approach applies across different ages, organs involved, and risk levels.

Across this month's papers, the clearest message is that side effects in Langerhans cell histiocytosis (LCH) can be very different depending on the treatment and the person. One report focused on skin and musculoskeletal problems during a BRAF-targeted medicine in an adult, while another focused on a severe lung infection during therapy in a young child. [14] [15]

A case report in a 78-year-old woman with BRAF V600E-mutant LCH described multiple new skin growths after starting dabrafenib, including eruptive moles on the palms and soles, warts, and a basal cell carcinoma (a type of skin cancer). [14]

The same patient also developed joint pains, which improved after the dabrafenib dose was reduced, and separately developed Dupuytren s contracture (hand tightening). Despite these side effects, a PET-CT scan at 4 months showed complete response of LCH in this single patient. [14]

For patients and caregivers, this is mainly a reminder that targeted treatments can come with noticeable skin changes and sometimes joint or hand symptoms, and that these may happen relatively early in treatment. Because this evidence comes from a single person, it cannot predict how common these effects are or who will develop them, but it provides concrete examples clinicians watch for in adults receiving BRAF-targeted therapy.

This month's infection-related paper highlights that, during treatment for multisystem LCH, uncommon infections can sometimes become severe and affect breathing. The evidence here is limited to one child, but it shows what severe respiratory infection can look like and how intensive supportive care may be used.

In a case report of a 3-year-old boy with multisystem LCH during consolidation therapy, Pneumocystis jirovecii pneumonia (PJP) caused severe respiratory failure after standard approaches were not enough. The child was supported with venovenous extracorporeal membrane oxygenation (ECMO), improved quickly enough to come off ECMO on day 6 and be extubated by day 8, and imaging changes resolved within 2 weeks. [15]

The report noted Pneumocystis jirovecii was confirmed on bronchoalveolar lavage testing, and there was also Klebsiella pneumoniae present. After completing antimicrobial treatment, the child resumed maintenance chemotherapy and was reported to be well at 10-month follow-up on secondary PJP prophylaxis. [15]

For families, this report is most useful as background on the range of infection risks that can occur during therapy, especially for children with multisystem LCH. Because it is a single case, it does not show how often PJP occurs in LCH or which treatments raise risk the most, but it documents that recovery is possible even after very severe respiratory failure with specialized intensive care.

Across these papers, the main message is that Langerhans cell histiocytosis (LCH) can show up in less expected places and look like more common conditions, especially early on. Two single-patient reports highlighted uncommon starting symptoms in very young children, while a larger evidence summary suggested that mouth and jaw involvement is not rare, although study quality was low. Together, they reinforce that LCH can involve skin, salivary glands, lungs, and the mouth, but the exact frequency and typical patterns still vary across studies. [16] [17] [18]

One case report described a newborn with widespread bleeding blisters (hemorrhagic vesicles) as the first sign of LCH after infections were ruled out and the diagnosis was confirmed on skin tissue testing. The skin lesions cleared over about 3 to 4 weeks, and there was no recurrence reported at 2 months, but this was only one infant so it may not apply to others. [16]

Another case report described a 17-month-old with scalp scaling and swelling of both parotid glands (major salivary glands), who then developed sudden breathing distress and was found to have extensive lung involvement. The authors noted that bilateral parotid involvement and cyst-like lung disease are considered rare presentations in pediatric LCH, and the diagnosis was supported by a skin biopsy. [17]

A systematic review and meta-analysis of 16 studies estimated that mouth-related LCH signs occur in about 14.86% of patients, dropping to 10.57% in sensitivity analyses, but the studies varied widely and the overall certainty was rated low. The lower jaw (mandible) and gums were most often affected, and reported problems included gum swelling, mouth ulcers, loose teeth, and jawbone loss seen on imaging. [18]

For patients and caregivers, this group of studies mainly serves as background about where LCH can appear and how it may sometimes look unusual, particularly in very young children. The two case reports cannot tell how often these rare starting symptoms happen, but they document that skin, salivary glands, and lungs can be involved in unexpected ways. The meta-analysis suggests mouth and jaw involvement may affect around 1 in 10 to 1 in 7 people with LCH, but there is still uncertainty because the included studies were inconsistent and mostly retrospective. [16] [17] [18]

Across this report, the main pattern is that Langerhans cell histiocytosis (LCH) can leave lasting health issues that continue into adulthood, and some problems may slowly worsen years after the original disease was treated. The reported late effects involved the brain (coordination and swallowing), hormone control centers (the pituitary area), and bone strength, highlighting the need for long-term, multi-specialty follow-up in some survivors. Because this is a single-person report, it cannot tell how common these late effects are. [19]

In one 30-year-old man who had multisystem LCH in childhood, progressive cerebellar dysfunction developed over time, with imbalance, gait instability, slurred speech, and swallowing difficulty. Brain imaging did not show clear signs of active central nervous system LCH, suggesting the symptoms may reflect long-term injury rather than new active disease. These kinds of symptoms can affect walking safety, eating, and communication in daily life. [19]

The same person had chronic hypothalamic-pituitary problems, including central diabetes insipidus and growth hormone deficiency, with pituitary MRI changes such as a thin pituitary stalk and very small anterior pituitary gland. He also had severe skeletal fragility with very low bone density and a history of recurrent low-trauma fractures and back pain. Together, this shows how endocrine (hormone) late effects and bone health can be closely linked in long-term survivorship. [19]

For patients and caregivers, this report is most relevant as a reminder that survivorship after childhood or multisystem LCH can include late effects involving balance/coordination, hormone function, and bone strength, even decades later. It provides detailed examples of what these long-term issues can look like, but it does not show how often they happen or who is at highest risk. Larger survivorship studies are still needed to clarify how common these problems are and which follow-up approaches best reduce long-term disability and fracture risk. [19]

This month included one detailed case report suggesting that, at least in rare situations, Langerhans cell histiocytosis (LCH) and a separate blood disorder can come from a shared early cell population that later splits into different disease paths. The report highlights how gene testing of both bone marrow and skin lesions can help clarify whether two diagnoses may be biologically linked. Because this is a single-patient description, it cannot show how often this happens or whether it changes outcomes for most people with LCH. [20]

In this 63-year-old man, LCH developed in the setting of polycythemia vera (a bone marrow condition that can cause high blood counts). Genetic testing found the same ARAF, IDH2, and ASXL1 gene changes in both the bone marrow and the skin, supporting a shared origin, while the JAK2 change (often seen in polycythemia vera) appeared later, fitting a "branching" pattern where one early clone evolves into more than one disease. [20]

The patient had a diffuse, non-itching skin eruption and a complex clinical course with multiple treatments used over time, but responses were variable. He ultimately died from infectious complications, which the authors reported as part of the overall disease and treatment history in this single case. [20]

For patients and caregivers, this report mainly adds background about how LCH can sometimes relate to other bone marrow or blood conditions at the genetic level, rather than being an entirely separate event. Right now, the main uncertainty is how common this shared-origin pattern is, and whether identifying it reliably changes care or long-term results, since the evidence here comes from only one person. [20]